SteelPeak Wealth LLC Has $671,000 Stake in Novo Nordisk A/S (NYSE:NVO)

SteelPeak Wealth LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 70.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,801 shares of the company’s stock after buying an additional 3,220 shares during the quarter. SteelPeak Wealth LLC’s holdings in Novo Nordisk A/S were worth $671,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of NVO. International Assets Investment Management LLC lifted its holdings in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. Mediolanum International Funds Ltd acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth about $98,765,000. Wellington Management Group LLP bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $42,017,000. World Investment Advisors LLC grew its position in shares of Novo Nordisk A/S by 2,655.9% in the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after purchasing an additional 270,234 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Novo Nordisk A/S by 71.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 475,490 shares of the company’s stock worth $57,413,000 after purchasing an additional 198,891 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on NVO shares. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $85.33 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The business has a 50-day moving average of $94.32 and a 200-day moving average of $113.82. The stock has a market capitalization of $382.91 billion, a price-to-earnings ratio of 27.61, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.